PXD040478-1

PXD040478 is an original dataset announced via ProteomeXchange.

Title	Phosphoproteomics measurement of clonal endocrine therapy sensitive and resistant breast cancer populations
Description	Around two thirds of breast tumors are characterized by the expression of estrogen receptor α and are therapeutically treated by blocking estrogen signaling. First line endocrine therapeutics are Tamoxifen which displaces estrogen form its receptor preventing receptor activation and aromatase inhibitors which prevent the formation of estrogen and thereby hormone-deprive the tumors. Therapy resistance remains a major clinical problem, especially for patients with late-stage diagnoses. Tumor heterogeneity may promote therapy resistance either through the selection of pre-existing rare clones or by providing a repertoire of cells that may develop resistance over time. In order to study endocrine therapy resistance on a clonal level, we have developed barcoded (allowing the tracking of single cells) endocrine therapy sensitive and resistant breast cancer cell lines. From these complex cell pools, multiple single cells characterized by a specific barcode were isolated and grown out. We then subjected the clones to phosphoproteomics measurement by Mass spectrometry. Based on their phosphorylation pattern, the kinase activity profiles of endocrine therapy resistant clones were determined to identify differentially activated kinases with implications in therapy resistance.
HostingRepository	PRIDE
AnnounceDate	2024-01-27
AnnouncementXML	Submission_2024-01-26_17:11:16.849.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Lukas Beumers
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	phosphorylated residue; acetylated residue; monohydroxylated residue; iodoacetamide derivatized residue
Instrument	Orbitrap Exploris 480

Revision	Datetime	Status	ChangeLog Entry
0	2023-02-27 10:01:43	ID requested
⏵ 1	2024-01-26 17:11:18	announced

Beumers L, Vlachavas EI, Borgoni S, Schwarzm, ü, ller L, Penso-Dolfin L, Michels BE, Sofyali E, Burmester S, Heiss D, Wilhelm H, Yarden Y, Helm D, Will R, Goncalves A, Wiemann S, Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets. NPJ Breast Cancer, 9(1):97(2023) [pubmed]

10.1038/s41523-023-00604-4;

submitter keyword: Phosphoproteomics, clonal deconvolution,Breast cancer, therapy resistance

Prof. Dr. Stefan Wiemann
contact affiliation	Molekulare Genomanalyse (B050) Deutsches Krebsforschungszentrum Im Neuenheimer Feld 580 69120 Heidelberg Germany
contact email	s.wiemann@dkfz.de
lab head
Lukas Beumers
contact affiliation	DKFZ Heidelberg
contact email	l.beumers@dkfz-heidelberg.de
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/01/PXD040478

PRIDE project URI

• PRIDE
  1. PXD040478
     1. Label: PRIDE project
     2. Name: Phosphoproteomics measurement of clonal endocrine therapy sensitive and resistant breast cancer populations